Payment overview · 2025
General Payments
$672.29
33 reported records · 12 companies
Healthcare provider profile · identity verified
Robert Gutierrez, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · NORTH PORT, FL · NPI 1952388795
Verified facts
What the public records show
CMS Open Payments records show Robert Gutierrez, D.O. received $672.29 in general payments during 2025 across 33 reported records.
Novo Nordisk Inc accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.81 | 25.9% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.24 | 12.5% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $82.33 | 12.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $74.28 | 11.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.77 | 9.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.33 | 8.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.80 | 6.7% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.09 | 4.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.52 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.95 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.99 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.18 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $672.29 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $151.05 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $121.75 | 6 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $82.33 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $74.28 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $67.26 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.26 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $57.33 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.33 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.80 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 187 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 173 |
| Lisinopril | Lisinopril | 532 | 150 |
| Omeprazole | Omeprazole | 495 | 139 |
| Losartan Potassium | Losartan Potassium | 433 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 347 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 94 |
| Alprazolam | Alprazolam | 314 | 74 |
| Simvastatin | Simvastatin | 312 | 86 |
| Tramadol Hcl | Tramadol Hcl | 306 | 73 |
| Metformin Hcl | Metformin Hcl | 282 | 95 |
| Trazodone Hcl | Trazodone Hcl | 252 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 237 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 230 | 66 |
| Furosemide | Furosemide | 219 | 75 |
| Gabapentin | Gabapentin | 215 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 193 | 42 |
| Glimepiride | Glimepiride | 190 | 55 |
| Eliquis | Apixaban | 187 | 44 |
| Montelukast Sodium | Montelukast Sodium | 187 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 55 |
| Allopurinol | Allopurinol | 185 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 52 |
| Potassium Chloride | Potassium Chloride | 164 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 46 |
| Atenolol | Atenolol | 155 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 43 |
| Famotidine | Famotidine | 141 | 45 |
| Lorazepam | Lorazepam | 133 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 40 |
| Sertraline Hcl | Sertraline Hcl | 124 | 37 |
| Ozempic | Semaglutide | 118 | 22 |
| Buspirone Hcl | Buspirone Hcl | 115 | 23 |
| Alendronate Sodium | Alendronate Sodium | 109 | 31 |
| Carvedilol | Carvedilol | 106 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 28 |
| Meloxicam | Meloxicam | 101 | 33 |
| Spironolactone | Spironolactone | 100 | 31 |
| Ezetimibe | Ezetimibe | 98 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 24 |
| Finasteride | Finasteride | 81 | 24 |
| Clonazepam | Clonazepam | 79 | 15 |
| Warfarin Sodium | Warfarin Sodium | 78 | 26 |
| Prednisone | Prednisone | 77 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 29 |
| Synthroid | Levothyroxine Sodium | 76 | 19 |
| Celecoxib | Celecoxib | 72 | 24 |
| Metformin Hcl Er | Metformin Hcl | 71 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 20 |
| Farxiga | Dapagliflozin Propanediol | 65 | 11 |
| Methylprednisolone | Methylprednisolone | 64 | 52 |
| Pregabalin | Pregabalin | 64 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 19 |
| Donepezil Hcl | Donepezil Hcl | 59 | 22 |
| Estradiol | Estradiol | 59 | 14 |
| Terazosin Hcl | Terazosin Hcl | 59 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 50 |
| Azelastine Hcl | Azelastine Hcl | 57 | 18 |
| Temazepam | Temazepam | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 18 |
| Jardiance | Empagliflozin | 54 | 16 |
| Amoxicillin | Amoxicillin | 53 | 41 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 13 |
| Mirtazapine | Mirtazapine | 50 | 14 |
| Valsartan | Valsartan | 50 | 14 |
| Bupropion Xl | Bupropion Hcl | 49 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Nystatin | Nystatin | 45 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | 11 |
| Levetiracetam | Levetiracetam | 38 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Diazepam | Diazepam | 31 | 11 |
| Gemfibrozil | Gemfibrozil | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Glipizide | Glipizide | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $672.29 · 33 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, CAPVAXIVE, COMIRNATY, ELIQUIS, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error